ClinicalTrials.gg
CompletedNCT04588727Updated Dec 18, 2023

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

A Phase 1 interventional study of AZD3366 and Placebo in Cardiovascular Disease, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-18.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single intravenous (IV) ascending doses.

Part B of this study is a randomized, single-blind, parallel group placebo-controlled study to assess the safety, tolerability and PD of a single IV administration of AZD3366 with concomitant loading doses followed by repeated maintenance dosing of ticagrelor and acetylsalicylic acid (ASA).

Read the detailed description

The study will provide data on safety, tolerability, PK, and PD of AZD3366 in healthy subjects. Three populations (healthy subjects, healthy Japanese subjects and healthy Chinese subjects) will be enrolled into this study.

This study will be conducted at a single study center in United States of America (USA).

Part A of the study will investigate the safety, tolerability, PK, and PD (inhibition of platelet aggregation and capillary bleeding time [CBT]) of an IV administration of single ascending doses (SAD) of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects.

Part B of the study will investigate the safety, tolerability, and PD (inhibition of platelet aggregation and CBT) of a single IV dose of AZD3366 or placebo with concomitant administration of ticagrelor and ASA by a parallel group cohort consisting of of healthy subjects. Furthermore, the potential effect of AZD3366 on the PK of ticagrelor will be investigated. Co-medication with ASA and ticagrelor is chosen based on the Standard of Care anti-platelet treatment regimen in patients with myocardial infarction.

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Pharmacokinetics
  • Cardiovascular disease
  • Acute myocardial infarction
  • Acute ischemic stroke
  • First in Human
  • Healthy subjects
  • Healthy Japanese subjects
  • Healthy Chinese subjects
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.

This study's enrollment of 103 is close to the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy men and women of non-
  2. Females must have a negative pregnancy test at Screening and on admission to the study center, must not be lactating, and must be of non-childbearing potential, confirmed at Screening, by fulfilling one of the below criteria:

    • defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and Follicle stimulating hormone levels in the postmenopausal range.
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not bilateral tubal ligation.
  3. Subjects described as healthy subjects are defined as not having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent [for example, Cambodia, China, India, Indonesia, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam] except for subjects enrolled into the Japanese (subject for whom both parents and all grandparents are Japanese; born in Japan and not lived outside Japan for more than 10 years) and Chinese (a subject for whom both parents and all grandparents are Chinese and not lived outside of China for more than 10 years) cohorts.
  4. : 18 and 30 kg/m\^2, and weigh minimum 50 kg and not >100 kg.

Exclusion criteria

Exclusion Criteria:

  1. Subjects having history of the following are excluded:

    • Any disease or disorder which, may put the subject at risk, or influence the results or the subject's ability to participate in the study.
    • History or presence of gastrointestinal, hepatic or renal disease or other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
    • Hemophilia, von Willebrand´s disease, lupus anticoagulant or other diseases/syndromes that can either alter or increase the propensity of bleeding.
    • Any clinically significant non-traumatic bleed or clinically significant enhanced bleeding.
    • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of medicinal product (IMP).
    • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD3366 or to ASA or ticagrelor.
  2. Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results, coagulation parameters, including but not limited to the list below:

    • > (ULN)
    • Aspartate aminotransferase > ULN
    • Creatinine > ULN
    • White blood cell count \< lower limit of normal (LLN)
    • \< LLN
    • count \< 150,000/µL
    • Total 1.2 x > ULN
  3. Subjects with positive serum surface antigen, antibody and .
  4. Any abnormal vital signs, after 10 minutes supine rest, as defined in the list below, at the Screening Visit and/or Day -1:

    • Systolic blood pressure (BP) \< 90 mmHg or > 140 mmHg.
    • Diastolic BP \< 50 mmHg or > 90 mmHg.
    • Heart rate \<45 or >85 beats per minute.
  5. Any clinically important abnormalities in rhythm, conduction or morphology of resting (ECG) and any clinically important abnormalities in the 12-lead ECG, which may interfere with the interpretation of changes, including abnormal ST-T-wave morphology.
  6. Current smokers or those who have smoked or used nicotine products within the previous 3 months, or history of alcohol abuse or excessive intake of alcohol.
  7. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
  8. Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega-dose vitamins and minerals during the 2 weeks prior to the first administration of IMP or 5 x the half-life of the drug (whichever is longer).
  9. Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
  10. COVID-19 vaccination has been administered and a period of less than 14 days has elapsed after the second dose of the vaccine prior to randomization.
  11. Received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days (or 5 half-lives, whichever is longer) of the first administration of IMP in this study.
  12. Scheduled surgery, including dental surgery, within 8 weeks of the scheduled completion date of the study.
  13. Anti-platelet therapy, anticoagulation therapy (i.e., warfarin, factor Xa inhibitors, direct thrombin inhibitors, or heparin), or thrombolytic use, in the past month prior to randomization or planned use during the duration of the study.
  14. Use of non-steroidal anti-inflammatory drugs (including ibuprofen) within 3 days prior to the randomization.
  15. Use of potent cytochrome 3A4/3A5 and/or P-glycoprotein inhibiting or inducing drugs during the 2 weeks prior to the first administration of IMP or 5 x the half-life of the drug (whichever is longer).
  16. Subjects who are vegans.
  17. Subjects who cannot communicate reliably with the investigator.
  18. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    AZD3366 Dose 1 Part A

    Randomized healthy subjects will receive Dose 1 of AZD3366.

    Drug: AZD3366

  • Experimental
    AZD3366 Dose 2 Part A

    Randomized healthy subjects will receive Dose 2 of AZD3366.

    Drug: AZD3366

  • Experimental
    AZD3366 Dose 3 Part A

    Randomized healthy subjects will receive Dose 3 of AZD3366.

    Drug: AZD3366

  • Experimental
    AZD3366 Dose 4 Part A

    Randomized healthy subjects will receive Dose 4 of AZD3366.

    Drug: AZD3366

  • Experimental
    AZD3366 Dose 5 Part A

    Randomized healthy subjects and healthy Japanese subjects will receive Dose 5 of AZD3366.

    Drug: AZD3366

  • Experimental
    AZD3366 Dose 6 Part A

    Randomized healthy subjects and healthy Japanese subjects will receive Dose 6 of AZD3366.

    Drug: AZD3366

  • Experimental
    AZD3366 Dose 7 Part A

    Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Dose 7 of AZD3366.

    Drug: AZD3366

  • Placebo comparator
    Placebo Part A

    Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Placebo matched to AZD3366.

    Drug: Placebo

  • Experimental
    AZD3366 Dose X Part B

    Randomized healthy subjects will receive Dose X of AZD3366 in conjunction with concomitant administration of ticagrelor and ASA.

    Drug: AZD3366 · Drug: Ticagrelor · Drug: acetylsalicylic acid (ASA)

  • Placebo comparator
    Placebo Dose X Part B

    Randomized healthy subjects will receive Dose X of placebo in conjunction with concomitant administration of ticagrelor and ASA.

    Drug: Placebo · Drug: Ticagrelor · Drug: acetylsalicylic acid (ASA)

Interventions

  • DrugAZD3366

    In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).

  • DrugPlacebo

    In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).

  • In Part B, subjects will receive oral ticagrelor tablets.

    Also known as: Brilinta

  • In Part B, subjects will receive oral ASA chewable tablets.

    Also known as: Chewable aspirin

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events and serious adverse events in both Part A and Part B

    Adverse events will be assessed to investigate the safety and tolerability of intravenous administration of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects.

    Time frame: From screening (Day -21) to follow-up (Day 60 for Part A and Day 50 for Part B)

Secondary outcomes

  1. Area under plasma concentration-time curve from time zero extrapolated to infinity (AUCinf) to characterize the PK of AZD3366 in Part A

    To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose, and post-dose (Day 1 to Day 60)

  2. Terminal half life (t½λz), estimated as (ln2)/λz to characterize the PK of AZD3366 in Part A

    To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose, and post-dose (Day 1 to Day 60)

  3. Total body clearance of drug from plasma after intravascular administration (CL) to characterize the PK of AZD3366 in Part A

    To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose, and post-dose (Day 1 to Day 60)

  4. Volume of distribution at steady state from a systemic dose (Vss) to characterize the PK of AZD3366 in Part A

    To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose, and post-dose (Day 1 to Day 60)

  5. Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUClast) to characterize the PK of AZD3366 in Part A

    To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose, and post-dose (Day 1 to Day 60)

  6. Area under the plasma concentration-time curve from time zero to 48 hours after dosing [AUC(0-48)] to characterize the PK of AZD3366 in Part A

    To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose, and post-dose (Day 1 to Day 60)

  7. Observed maximum plasma concentration (Cmax) to characterize the PK of AZD3366 in Part A

    To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose, and post-dose (Day 1 to Day 60)

  8. Time to reach peak or maximum observed concentration following drug administration (tmax) to characterize the PK of AZD3366 in Part A

    To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose, and post-dose (Day 1 to Day 60)

  9. To study the platelet aggregration of AZD3366 in Part A

    To study platelet aggregation by Light Transmision Aggregometry (LTA) in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose, and post-dose (Day 1 to Day 60)

  10. Assessment of the duration of capillary bleeding time (CBT) to characterize the PD of AZD3366 in Part A

    To characterize the PD of AZD3366 following IV administration of single doses of AZD3366 with respect to inhibition of CBT in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.

    Time frame: Pre-dose and post-dose (Day 1)

  11. Collection of blood samples for the analyses of antidrug antibodies (ADAs) in both Part A and Part B

    To explore immunogenicity following IV administration of AZD3366 in both Part A and Part B.

    Time frame: At Day -1, Day 15, Day 23 and Day 44 in Part A, and pre-dose (Day 1), Day 15, Day 29 and Day 50 in Part B

  12. Collection of blood samples for adenosine diphosphate-induced associated periodic-induced platelet aggregation in platelet-rich plasma to characterize the PD of AZD3366 in Part B

    To study the plasma exposure and characterize the PD of AZD3366 with respect to inhibition of platelet aggregation LTA, following IV administration of AZD3366 at one dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)

  13. Collection of blood samples for tumor necrosis factor receptor associated periodic-induced platelet aggregation in platelet-rich plasma to characterize the PD of AZD3366 in Part B

    To study the plasma exposure and characterize the PD of AZD3366 with respect to inhibition of platelet aggregation LTA, following IV administration of AZD3366 at one dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)

  14. CBT to characterize the PD of AZD3366 in Part B

    To study the PD (inhibition of CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.

    Time frame: Pre- dose and post-dose (Day 1 and Day 3)

  15. AUClast to characterize the plasma exposure and PD of AZD3366 in Part B

    To study the plasma exposure, and PD (inhibition of platelet aggregation and CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)

  16. AUC(0-48) to characterize the plasma exposure and PD of AZD3366 in Part B

    To study the plasma exposure, and PD (inhibition of platelet aggregation and CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)

  17. Cmax to characterize the plasma exposure and PD of AZD3366 in Part B

    To study the plasma exposure, and PD (inhibition of platelet aggregation and CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)

  18. tmax to characterize the plasma exposure and PD of AZD3366 in Part B

    To study the plasma exposure, and PD (inhibition of platelet aggregation and CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)

  19. AUCinf to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B

    To study the effect of AZD3366 on the PK of ticagrelor in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3)

  20. AUClast to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B

    To study the effect of AZD3366 on the PK of ticagrelor in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3)

  21. tmax to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B

    To study the effect of AZD3366 on the PK of ticagrelor in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3)

  22. t½λz to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B

    To study the effect of AZD3366 on the PK of ticagrelor in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3)

  23. Area under the plasma concentration-time curve from time zero to 12 hours after dosing [AUC(0-12)] to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B

    To study the effect of AZD3366 on the PK of ticagrelor in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3)

  24. Cmax to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B

    To study the effect of AZD3366 on the PK of ticagrelor in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3)

  25. Observed trough plasma concentration after the first dose (Ctrough) to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B

    To study the effect of AZD3366 on the PK of ticagrelor in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3)

  26. Arithmetic mean of plasma concentration (C) at 12, 24, 36 and 48 hrs post-dose [Cmean (12, 24, 36, 48 hrs)] to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B

    To study the effect of AZD3366 on the PK of ticagrelor in Part B.

    Time frame: Pre-dose and post-dose (Day 1 to Day 3)

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please re-refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jan 2022, 15 months.

Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2020
First posted
Oct 19, 2020
StartActual
Oct 15, 2020
Primary completionActual
Jan 19, 2022
CompletionActual
Jan 19, 2022
Last update
Dec 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04588727
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Oct 15, 2020
Primary completion
Jan 19, 2022
Completion
Jan 19, 2022
Last update
Dec 18, 2023

Study contacts

David Han
principal investigator · PAREXEL Early Phase Clinical Unit Los Angeles 1560 Chevy Chase Drive, Suite 140 Glendale, CA 91206 United States of America

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ticagrelor · Aspirin

Start the discussion